Healthcare
Live Price
Offline$23.00
-7.26% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CompuGroup Medical SE & Co. KGaA (CMPUY) is a Healthcare stock with a market cap of $1.19B. The stock last traded around $23.00. Baseline metrics include revenue growth of -2.8%, EPS growth of -23.9%, a dividend yield of 0.2%. What stands out right now is revenue -2.8%, EPS -23.9%, free cash flow -41.2% with operating margin 9.6% and ROIC 0.9%. The dividend is present but secondary, with a yield around 0.2%. Valuation already assumes a fairly strong business story at P/E 263.6 and price/sales 2.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CMPUY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CMPUY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CMPUY Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CMPUY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$837.3M
-18.3% YoY
FY Net Income
$73.2M
+6.1% YoY
Free Cash Flow
$94.2M
+7.3% YoY
Revenue Growth
-2.8%
EPS Growth
-23.9%
Gross Margin
83.4%
Net Margin
0.7%
Income statement
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.1B | 1.0B | 837M |
| Gross Profit | 965M | 1.0B | 958M | 871M | 713M |
| Operating Income | 106M | 122M | 126M | 109M | 120M |
| EBITDA | 207M | 213M | 228M | 214M | 192M |
| Net Income | 35M | 46M | 73M | 69M | 73M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 107M | 64M | 90M | 107M | 75M |
| Total Assets | 2.0B | 1.9B | 1.9B | 1.8B | 1.6B |
| Total Liabilities | 1.3B | 1.2B | 1.3B | 1.2B | 927M |
| Shareholder Equity | 648M | 668M | 672M | 612M | 639M |
| Total Debt | 880M | 767M | 786M | 741M | 555M |
| Net Debt | 773M | 703M | 696M | 634M | 480M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
150M
-9.3% YoY
Capital Expenditures
56M
+28.1% YoY
Free Cash Flow
94M
+7.3% YoY
Key ratios
Gross Margin
83.4%
Operating Margin
9.6%
Net Margin
0.7%
ROE
0.7%
Debt / Equity
1.27x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.